Huperzine A

Several findings below come from people with Alzheimer's disease, mild cognitive impairment or other diagnoses, and each section names the population. Results in clinical groups may not apply to healthy adults. We grade the evidence separately for each outcome; the evidence grading method explains what each grade requires.

Does huperzine A improve memory in healthy people?

The evidence we found is one small trial in adolescents [8]. In a 1999 double-blind trial, 34 matched pairs of junior middle school students who complained of poor memory took two 50 microgram capsules of huperzine A or placebo twice daily for 4 weeks [8]. At the end, memory quotient was 115 in the huperzine A group and 104 in the placebo group (P < 0.01) [8]. The trial was small, came from one research group and enrolled adolescents rather than adults [8].

A single-dose study in healthy young adults adds little [9]. Among several cholinesterase-inhibiting compounds tested against placebo, only huperzine A at 200 micrograms maintained declarative recall across test sessions, and no compound improved overall performance [9].

Clinical trials point in different directions [11][12]. In a randomized, double-blind, placebo-controlled trial in people with moderate-severe traumatic brain injury, a clinical population, memory performance did not differ from placebo after 12 weeks, and the placebo group improved significantly [11]. In a meta-analysis of 12 trials with 1,117 people with schizophrenia spectrum disorders taking antipsychotics, all conducted in China, adding huperzine A raised memory quotient by 10.59 points (95% CI 5.65 to 15.53) [12]. Results in clinical groups may not apply to healthy adults.

Does a single dose of huperzine A sharpen thinking?

Not in the two placebo-controlled studies we found [9][10]. In healthy young adults given a single dose of huperzine A (100 or 200 micrograms), one of two cholinesterase-inhibiting medicines or placebo, with 12 people per drug and dose, none of the compounds improved neurobehavioral performance, apart from maintained declarative recall with 200 micrograms of huperzine A [9]. The authors suggest this was likely due to ceiling effects in a young, healthy group [9].

A double-blind crossover trial tested 15 exercise-trained adults after a single 200 microgram dose or placebo [10]. No measure of cognitive function (digit span, verbal fluency and Stroop tests) differed between the two trials, and neuromuscular and exercise performance did not differ either [10]. Ratings of how difficult the exercise felt were significantly higher after huperzine A (6.8 versus 5.7 on a 0-10 scale) [10].

Both studies are small, so they show limited evidence of no effect rather than proof of none.

Does huperzine A affect overall cognition in clinical trials?

The trials here enrolled people with Alzheimer's disease, a clinical population, and results may not apply to healthy adults [1][2]. A 2008 Cochrane systematic review found six trials with 454 patients, most not of high methodological quality [1]. Compared with placebo, huperzine A raised scores on the MMSE, a screening test of overall cognition, by a weighted mean difference of 2.81 points (95% CI 1.87 to 3.76) [1]. It did not differ from placebo on the Wechsler Memory Scale (WMD 6.64; 95% CI -3.22 to 16.50) [1]. The authors judged that only one study was of adequate quality and size and that the evidence was inadequate to make any recommendation [1].

A 2013 meta-analysis pooled 20 randomized trials with 1,823 participants [2]. It found higher MMSE scores with huperzine A than with placebo at 8, 12 and 16 weeks, but most trials had a high risk of bias, the funnel plots suggested publication bias, and the authors said the findings should be interpreted with caution [2]. An overview of six systematic reviews reached the same conclusion: some benefit on cognition in Alzheimer's disease, little or no evidence in vascular dementia and mild cognitive impairment, and insufficient evidence overall because of heterogeneity and low-quality primary studies [3].

A phase II trial, co-funded by the NIH/NIA and Neuro-Hitech, Inc., was negative on its main outcome [4]. In that trial, 210 people with mild to moderate Alzheimer's disease were randomized to placebo or huperzine A at 200 or 400 micrograms twice daily for at least 16 weeks [4]. The 200 microgram dose did not change ADAS-Cog scores at 16 weeks, the primary outcome [4]. In secondary analyses, the 400 microgram dose showed a 2.27-point ADAS-Cog improvement at 11 weeks against a 0.29-point decline on placebo, but the difference at week 16 was not significant (p = 0.07) [4].

In other clinical groups the evidence is thinner or mixed [5][6][7][21]. A 2012 Cochrane review found no eligible placebo-controlled trials in mild cognitive impairment [5]. A 2019 meta-analysis of nine trials in mild cognitive impairment found higher memory quotient and MMSE scores with huperzine A, while noting the low quality of the studies [6]. A 2009 Cochrane review in vascular dementia found one trial of 14 participants, with no significant effect on MMSE [7]. A larger 2024 network meta-analysis in vascular dementia compared 21 drugs across 194 randomized trials, 16 of them testing huperzine A in 572 patients against 542 controls [21]. It placed huperzine A among the five most effective drugs on MMSE scores and on activities-of-daily-living scores [21]. The rankings rest partly on indirect comparisons, and doses, durations and patient groups varied across trials [21].

What the evidence does not show

The studies above do not show that huperzine A improves memory, attention or reaction time in healthy adults over weeks or months: the one repeated-dose trial we found outside a clinical population enrolled adolescents [8]. A 2023 review of 103 memory supplements described the huperzine A studies as having mixed results for memory [19]. The single-dose studies in healthy adults did not find better overall test scores, apart from maintained declarative recall at 200 micrograms in one study [9][10], and the exercise trial found no change in physical performance [10].

Huperzine A is absorbed quickly and cleared slowly [14][15]. In 12 healthy volunteers aged 20 to 25 given a 0.4 mg tablet, huperzine A appeared in plasma within 5-10 minutes and peaked at about 58 minutes [14]. Its elimination half-life (the time for the blood level to fall by half) was 716.25 minutes in that study [14], and about 12 hours in a crossover study in healthy Chinese men [15].

The effect on the enzyme outlasts the peak blood level [16]. In a phase Ib trial in healthy older adults, blood acetylcholinesterase inhibition ranged from 30-40% after 100 micrograms to more than 50% at 400 micrograms, peaking 1.5 hours after the dose [16]. Even 48 hours after the final 400 microgram dose in the escalating regimen, red blood cell acetylcholinesterase activity remained about 10% below its pre-dose level [16]. A pharmacokinetic model using data from 14 healthy elderly Chinese volunteers and 35 elderly Chinese people with Alzheimer's disease, a clinical population, found that age significantly affected how fast huperzine A is cleared [20].

On cycling: as of November 11, 2026 we found no trials comparing cycled with continuous use of huperzine A (PubMed search, November 11, 2026). Health Canada requires products providing huperzine A to tell people to ask a health care practitioner before use beyond 4 weeks [24].

In clinical trials, reported side effects were mostly mild and cholinergic [1][13]. The 2008 Cochrane review found adverse events were mild and did not differ significantly between huperzine A and control groups [1]. A 2009 meta-analysis of four trials found most adverse events were cholinergic in nature, with no serious events [13]. The 2013 meta-analysis found that 7 of 20 trials did not report adverse events at all [2]. In those that did, reported events included nausea (7 of 20 trials), loss of appetite, dizziness, vomiting, constipation, sweating and bradycardia, a slowed heart rate (2 of 20 trials), and no trial reported severe adverse events possibly related to huperzine A [2]. None of the six systematic reviews in the 2021 overview reported serious side effects [3].

In healthy volunteers, short studies reported good tolerability [15][16]. A crossover study in healthy men reported no adverse events and no abnormal laboratory results [15], and a dose-escalation trial in healthy older adults described doses up to 400 micrograms twice daily as well tolerated [16]. These studies were short and small.

Health Canada's monograph requires huperzine A products to tell users to stop and ask a health care practitioner if they experience dizziness, unusual muscle cramping, agitation, nausea, vomiting, diarrhea or excessive salivation [24]. It also requires a caution for people with a blood pressure or cardiovascular disorder [24].

A case report described poisoning in two adults who mistakenly drank tea made from a different club moss, the fir club moss Lycopodium selago, which contains huperzine A [18]. They developed sweating, vomiting, diarrhea, dizziness, cramps and slurred speech, symptoms the authors linked to a cholinergic mechanism [18]. This is a single case report.

The US Department of Defense's Operation Supplement Safety program (OPSS) lists decreased heart rate, nausea, vomiting, diarrhea, dizziness, sweating, blurred vision and insomnia as commonly reported adverse effects [27]. It says safety data are lacking and long-term use is not well understood, and advises caution [27].

Product quality is a documented problem, and it is the basis of our safety flag [17]. In a laboratory analysis of 22 US dietary supplements listing huperzine A, measured huperzine A ranged from below the limit of quantification to 267.1 micrograms per serving, and only two products were within 10% of the declared amount [17]. In the same study, 16 products (73%) contained compounds not on the label, and nine (41%) listed ingredients that do not meet FDA rules for dietary supplement ingredients [17]. The authors named stimulants among the ingredients of most concern that they detected [17].

Health Canada's monograph requires huperzine A products to tell people to ask a health care practitioner before use if they take medicines that affect acetylcholine levels, meaning cholinergic or anticholinergic drugs [24]. Cholinesterase-inhibiting medicines, such as galantamine and donepezil, which were approved for use in Alzheimer's disease, act on the same enzyme [9]. In a single-dose study in healthy adults, both huperzine A and galantamine inhibited blood acetylcholinesterase [9]. As of November 11, 2026, our search found no dedicated human study of interactions between huperzine A and a medicine (PubMed search, November 11, 2026). Trials in people with schizophrenia have given huperzine A alongside antipsychotic medicines, but they measured cognition rather than interactions, and adverse events were similar between groups [12]. OPSS reports that the Alzheimer's Association advises against huperzine A, especially with prescription drugs, citing a risk of serious side effects, and says combining it with other supplement ingredients, especially nootropics, might add risk [27]. A 2023 review of memory supplements says health care providers need to know about the supplements older patients take and their interactions with prescription medicines [19].

These sources describe what has been reported, not what is right for any individual. If you take any of these medicines, talk to your doctor or pharmacist before combining them with huperzine A.